Abbvie ((ABBV)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AbbVie is currently conducting a significant clinical study titled AndroMETa-CRC-064, aimed at evaluating the safety and efficacy of Telisotuzumab Adizutecan (ABBV-400) in comparison to the combination of LONSURF and Bevacizumab in patients with refractory metastatic colorectal cancer expressing high levels of c-Met protein. This study is crucial as colorectal cancer is one of the most prevalent cancers globally, and new treatments are needed to improve patient outcomes.
The study is testing Telisotuzumab Adizutecan, an investigational drug administered via intravenous infusion, against the standard treatment of LONSURF oral tablets combined with Bevacizumab IV infusion. The goal is to determine which treatment is more effective in managing the disease and minimizing adverse events.
This interventional study is designed as a randomized, sequential trial with no masking, focusing primarily on treatment. Participants are allocated to different treatment arms to receive either varying doses of Telisotuzumab Adizutecan or the standard care regimen.
The study began on November 8, 2024, with an estimated completion timeline of approximately four years. The most recent update was submitted on July 15, 2025, indicating ongoing recruitment and data collection.
For investors, the outcome of this study could significantly impact AbbVie’s market position, especially if Telisotuzumab Adizutecan proves to be a superior treatment option. This could enhance investor confidence and influence stock performance positively. In the competitive landscape of oncology, advancements in treatment options are closely watched by stakeholders.
The study is currently ongoing, with further details available on the ClinicalTrials portal.